05:02 AM EDT, 09/14/2026 (MT Newswires) -- BioNTech (22UA.F) and OncoC4 said Monday their gotistobart drug nearly doubled the survival of patients with squamous non-small cell lung cancer, citing data from stage 1 of the phase 3 trial Preserve-003. The Preserve-003 study is evaluating the CTLA-4-targeting immunotherapy gotistobart in patients whose disease progressed on prior immunotherapy and chemotherapy. The latest data showed that median overall survival among gotistobart-treated patients was 18.5 months, compared with 10 months for those who received the standard-of-care docetaxel. The clinical trial's stage 2 remains underway globally.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.